^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Published date:
09/21/2022
Excerpt:
Magrolimab+azacitidine was well tolerated, with promising effi cacy in patients with untreated HR MDS, including those with TP53-mutated and –wild-type disease.
Secondary therapy:
azacitidine
Trial ID: